Vistagen Therapeutics, Inc. Common Stock
$0.24
$0.01 (+2.74%)
$0.23Day Range$0.25
Key Statistics
Market Cap
$10.65M
Shares Outstanding
44.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 1, 2009
Round Lot
100
Locale
US
Trading Data
Day Open
$0.23
Day High
$0.25
Day Low
$0.23
Volume
718.6K
VWAP
$0.24
Prev Close
$0.23
Transactions
--
Acc. Volume
--
About Vistagen Therapeutics, Inc. Common Stock
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
PHARMACEUTICAL PREPARATIONSSIC 283441 employees343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080650-577-3600IPO Jul 1, 2009US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001411685
- Composite FIGI
- BBG000BB33L9
- Share Class FIGI
- BBG001S67BH3
- Ticker Root
- VTGN
- SIC Code
- 2834
About Vistagen Therapeutics, Inc. Common Stock (VTGN) Stock
Vistagen Therapeutics, Inc. Common Stock (VTGN) closed the 2026-09-18 session at $0.24, up 2.74% versus the previous close (+0.01). The stock opened at $0.23 and traded between $0.23 and $0.25 during that session. Session trading volume was 719K shares. The volume-weighted average price (VWAP) is $0.24.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Vistagen Therapeutics, Inc. Common Stock has a market capitalization of $10.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. VTGN is listed on the XNAS exchange. The company employs approximately 41 people. Vistagen Therapeutics, Inc. Common Stock is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2009-07-01.
On this page you can find market VTGN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.